Caroline R. M. Wiggers

Caroline R. M. Wiggers

Auto-generated profile, based on publicly available information

Caroline R. M. Wiggers

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
BCBas Castelijns
Bas Castelijns
MBMirna L. Baak
Mirna L. Baak
ITIlia S. Timpanaro
Ilia S. Timpanaro
CWCaroline R. M. Wiggers
Caroline R. M. Wiggers
MVMarit W. Vermunt
Marit W. Vermunt
MCMenno Pieter Creyghton
Menno Pieter Creyghton
Speciation is associated with substantial rewiring of the regulatory circuitry underlying the expression of genes. Determining which changes are relevant and underlie the emergence of the human brain or its unique susceptibility to neural disease has been challenging. Here we annotate changes to gene regulatory elements (GREs) at cell type resolution in the brains of multiple primate species spanning most of primate evolution. We identify a unique set of regulatory elements that emerged in hominins prior to the separation of humans and chimpanzees. We demonstrate that these hominin gains perferentially affect oligodendrocyte function postnatally and are preferentially affected in the brains of autism patients. This preference is also observed for human-specific GREs suggesting this system is under continued selective pressure. Our data provide a roadmap of regulatory rewiring across primate evolution providing insight into the genomic changes that underlie the emergence of the brain and its susceptibility to neural disease.

1 September 2019 in Cell Reports
Verified
Journal Article
Open access
CWCaroline R.M. Wiggers
Caroline R.M. Wiggers
MBMirna L. Baak
Mirna L. Baak
ESEdwin Sonneveld
Edwin Sonneveld
ENEdward E.S. Nieuwenhuis
Edward E.S. Nieuwenhuis
MBMarije Bartels
Marije Bartels
MCMenno P. Creyghton
Menno P. Creyghton
Relapse in acute myeloid leukemia (AML) may result from variable genetic origins or convergence on common biological processes. Exploiting the specificity and sensitivity of regulatory DNA, we analyze patient samples of multiple clinical outcomes covering various AML molecular subtypes. We uncover regulatory variation among patients translating into a transcriptional signature that predicts relapse risk. In addition, we find clusters of coexpressed genes within this signature selectively link to relapse risk in distinct patient subgroups defined by molecular subtype or AML maturation. Analyzing these gene clusters and the AML subtypes separately enhances their prognostic value substantially and provides insight in the mechanisms underlying relapse risk across the distinct patient subgroups. We propose that prognostic gene expression signatures in AML are valid only within patient subgroups and do not transcend these subgroups.

19 September 2025 in Leukemia
Verified
Journal Article
Open access
PDF file
JFJulia Frede
Julia Frede
JPJulia C. Poller
Julia C. Poller
KSKayleen Shi
Kayleen Shi
HSHannah Stuart
Hannah Stuart
NSNoori Sotudeh
Noori Sotudeh
JLJens G. Lohr
Jens G. Lohr
While most patients initially respond to CAR-T cell treatment, responses often are not durable and subsequent lines of immunotherapy show diminishing success. In this study, we investigated the co-evolutionary dynamics between CAR-T cells and the immune microenvironment in myeloma patients undergoing anti-BCMA CAR-T cell therapy at single-cell resolution. Our findings highlight the transformative impact of CAR-T cell treatment on the endogenous T cell landscape. We identify a novel transitional CD8 + T cell population that is predictive of poor treatment outcomes. The emergence of this population coincides with the depletion of the endogenous T cell repertoire and compositional evolution of functional T cell subsets. These changes in the endogenous T cell compartment induced by CAR-T cell therapy may contribute to inadequate immune capacity and tumor control. Our findings highlight the potential of targeting TIM3/GAL9 interactions to mitigate T cell exhaustion, apoptosis and lack of persistence, offering promising avenues for optimizing T cell-based cancer immunotherapies. We provide a framework for assessing and manipulating the ‘mileage’ of the immune system as predictive marker and therapeutic opportunity to prevent repeated immunotherapies from becoming increasingly less successful, even when targeting distinct antigens.

1 May 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
CWCaroline R.M. Wiggers
Caroline R.M. Wiggers
AGAnita M.A.P. Govers
Anita M.A.P. Govers
DLDaphne Lelieveld
Daphne Lelieveld
DEDavid A. Egan
David A. Egan
C Michel ZwaanC Michel Zwaan
C Michel Zwaan
MBMarije Bartels
Marije Bartels

1 August 2019 in HemaSphere
Verified
Journal Article
Open access
AGAnita M.A.P. Govers
Anita M.A.P. Govers
CWCaroline R.M. Wiggers
Caroline R.M. Wiggers
RBRuben van Boxtel
Ruben van Boxtel
MMMichal Mokry
Michal Mokry
ENEdward E.S. Nieuwenhuis
Edward E.S. Nieuwenhuis
PCPaul J. Coffer
Paul J. Coffer
Supplemental Digital Content is available in the text

21 November 2025 in Nature Communications
Verified
Journal Article
Open access
CWCaroline R. M. Wiggers
Caroline R. M. Wiggers
ECEugene Y. Cho
Eugene Y. Cho
MOMerve Ozdemir
Merve Ozdemir
GBGbolahan Bamgbose
Gbolahan Bamgbose
JHJustin Hegel
Justin Hegel
BKBirgit Knoechel
Birgit Knoechel
Changes in the immune microenvironment are frequent in cancers occurring in adult patients, yet our understanding of the pediatric cancer immune microenvironment and its clinical relevance is limited. We investigate the immune microenvironment in pediatric T cell acute lymphoblastic leukemia (T-ALL), using single-cell CITE-seq and immune repertoire analyses. We identify a T-ALL subgroup characterized by a remodeled immune microenvironment, which is associated with adverse clinical outcome in minimal residual disease low patients. This adverse immune landscape is dominated by the presence of a population of non-malignant CD4-CD8-TCRαβ T cells that interact with CXCL16 expressing non-classical monocytes. Leukemia cell intrinsic transcriptional rewiring in these patients is associated with activation of Rap1 signaling. Inhibiting Rap1 signaling results in increased sensitivity to the BCL2/BCL-XL inhibitor navitoclax. Our study provides insights into the immune microenvironment of pediatric hematologic malignancies, forming the basis for identifying potential (immuno) therapeutic targets and risk stratification for treatment.